Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 6/20 | 0.56 |
| ▸ | JAK2 | O60674 | 5/20 | 0.56 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059571 | 1.00 | JAK1 (0.56) | JAK1JAK2CDK19ALKAURKB | |
| SCHEMBL16336889 | 1.00 | JAK1 (0.56) | JAK1JAK2CDK19ALKAURKB | |
| SCHEMBL15060022 | 0.94 | JAK1 (0.58) | JAK1JAK2CDK19ALKAURKB | |
| Hydrochloric Acid SCHEMBL15059314 | 0.93 | JAK1 (0.57) | JAK1JAK2CDK19ALKAURKB | |
| SCHEMBL15059873 | 0.88 | CDK19 (0.58) | JAK1JAK2CDK19ALKAURKB | |
| Hydrochloric Acid SCHEMBL15059309 | 0.83 | JAK1 (0.55) | JAK1JAK2CDK19ALKAURKB | |
| Hydrochloric Acid SCHEMBL15059491 | 0.83 | JAK1 (0.55) | JAK1JAK2CDK19ALKAURKB | |
| SCHEMBL16513453 | 0.83 | JAK1 (0.71) | JAK1JAK2CDK19ALKAURKB | |
| SCHEMBL16336520 | 0.83 | JAK1 (0.52) | JAK1JAK2AURKBSYKKDR | |
| SCHEMBL15059525 | 0.82 | JAK2 (0.55) | JAK1JAK2AURKBKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3421462-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2021-09-30 | — | — | US | disclosed |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696658-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10421744-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3013813-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190002439-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3421462-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10093655-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9139561-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | JAK1 1585/4885JAK2 1030/4885CDK19 389/4885 |
| US-10421744-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD1, SNCA, DRD2 | JAK1 2291/4885JAK2 3695/4885CDK19 2380/4885 |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | JAK1 1585/4885JAK2 1030/4885CDK19 389/4885 |
| US-20190002439-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, SNCA, DRD2 | JAK1 2291/4885JAK2 3695/4885CDK19 2380/4885 |
| US-10093655-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD1, SNCA, DRD2 | JAK1 2291/4885JAK2 3695/4885CDK19 2380/4885 |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | JAK1 2325/4885JAK2 4079/4885CDK19 2085/4885 |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885CDK19 98/4885 |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | JAK1 1585/4885JAK2 1030/4885CDK19 389/4885 |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, SNCA | JAK1 2604/4885JAK2 3578/4885CDK19 2672/4885 |
| US-10696658-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD1, SNCA, DRD2 | JAK1 2291/4885JAK2 3695/4885CDK19 2380/4885 |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, SNCA | JAK1 2604/4885JAK2 3578/4885CDK19 2672/4885 |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, SNCA, DRD2 | JAK1 2291/4885JAK2 3695/4885CDK19 2380/4885 |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, HTR1D, DRD1 | JAK1 1548/4885JAK2 752/4885CDK19 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.